Compare Boston Scientific Corporation (BSX) vs Redwire Corporation (RDW) Price & Performance

Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.

BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.

RDW stock trades at $13.59, up 14.88% in the last 24 hours, reflecting strong momentum after Q2 2026 results. The company reported record revenue of $117.1 million and a growing backlog of $542.1 million, though it remains unprofitable with a net income margin of -57.26%. Technical indicators show a bullish trend, with the current price near the consensus target of $17.50, while analyst sentiment is overwhelmingly positive with 80% buy ratings.

The outlook hinges on execution of its space and defense contracts, but persistent losses and negative cash flows from operations pose significant risks. Upside potential exists if margin improvements materialize, yet investors face volatility from earnings misses and high burn rates.